and can pass easily through the kidney (Bickel et al., 1960) . Desferrioxamine has been used in an attempt to reduce iron deposit in several diseases associated with iron accumulation, and the results on the whole suggest a beneficial effect (Bannerman, Callender, and Williams, 1962; Nielsen, 1963; Wohler, 1963; Moeschlin and Schnider, 1963; Santos and Pisciotta, 1964) . Few references, however, are available on the effect of desferrioxamine on renal excretion of iron in thalassaemia (Sephton Smith, 1962; Bannerman et al., 1962; Wohler, 1963) .
We have studied the effect of desferrioxamine on iron excretion in 13 cases of thalassaemia major in children.
Material and Methods Thirteen children with thalassaemia major syndrome were chosen for the present study. clinical, haematological, and biochemical features of thalassaemia. Two patients were designated as advanced or modetately severe, according to the duration and severity of the disease. Advanced cases were those children with a history of repeated blood transfusions at monthly intervals or more frequently, for the last 2 years. Moderately severe cases were those who either gave no history of blood transfusion or had less than one blood transfusion every 6 months for the last 2 years. 24-hour urine excretions were analysed for iron content 2 days before starting therapy, to determine the average daily iron output. The urine was washed with concentrated sulphuric acid and the iron content of the decomposition solution was determined colorimetrically using oc, oc-dipyridyl (Keberl, 1964) . Since the optimal dosage for desferrioxamine* has not been established, the drug was originally administered intramuscularly in a dose of 500 mg. daily. This proved to give very low renal iron excretion figures. The dose was later increased to 1000 mg. daily in two 12 hourly 500 mg. doses. This gave appreciably higher iron excretion figures and was the dose used for all patients throughout the study. Desferrioxamine was administered for a period of 5 days consecutively. Urinary iron content was estimated daily during this period, as well as on the 6th and 7th days after desferrioxamine had been discontinued. Serum iron and unsaturated iron-binding capacity (Ramsay, 1958) were estimated in all cases immediately before and after the 5-day course of desferrioxamine (except in 3 cases).
Hb, reticulocyte counts, and bone-marrow samples were done just before and 2 days after stopping the therapy in 6 cases. Table I shows the urinary excretion of iron (mg./ 24 hours urine) before, during, and after desferrioxamine therapy. Patients are separated into 2 groups -advanced and moderately severe. Significant difference in iron excretion between the two groups is evident. Table II shows the serum iron and unsaturated iron-binding capacity before and after therapy with desferrioxamine. Fig. 1 and 2 illustrate diagrammatically the effect excretion in thalassaemia major gave slightly higher excretion figures than those observed in the present study (Bannerman et al., 1962; Wohler, 1963) . This might be related to the fact that most of these cases were older children with a higher iron load. It is evident from Table I that desferrioxamine is more effective in advanced cases with a greater iron load.
Results
The effectiveness of the drug in minimizing iron deposition, with its sequelae in thalassaemia major, is difficult to decide without long follow-up studies on individual cases. As shown in Table I , the mean maximal excretion figure for urinary iron under desferrioxamine was 4 52 mg./day (on the 3rd day); this would amount to 135 mg./month. Most of these children, however, receive on the average 500 ml. blood monthly, with an average iron content of 250 mg. (50 mg./100 ml. blood) (King and Wootton, 1956) . It is thus evident that even with maximal efficiency and daily desferrioxamine administration iron output still lags behind iron intake. This is even more pronounced if oral iron Case 3 intake in the diet is taken into consideration. Oral absorption of iron is not affected by intramuscular desferrioxamine administration (Stevens et al., 1962) . However, until more effective chelating agents or other ways of eliminating iron are available, the use of desferrioxamine is indicated in all cases of thalassaemia in an attempt to minimize the iron overload to which these patients are subjected. Intravenous infusion of larger doses at the time of each blood transfusion might be more effective in iron elimination. The slight risk of the development of cataract following prolonged therapy with desferrioxamine necessitates periodic ophthalmic screening.
Since desferrioxamine liberates iron from iron stores, a temporary rise in serum iron, with lowering of iron-binding capacity, is to be expected immediately after therapy. This was seen in most of our cases. The same observation was also noted by Wohler (1963) .
An important observation in the present study is the reticulocyte response observed in 4 out of 6 patients followed up after desferrioxamine administration in the presence of similar haemoglobin levels. This reticulocyte response was associated with evidence of increased normoblastic reaction of the bone-marrow (Table III) . That desferrioxamine is a substance possessing oxidative properties has been reported by Wohler (1963) , who also thought that it had some effect on the synthesis of haem in achrestic anaemia. He mentioned that this paralleled the excretion of iron promoted by desferrioxamine. He suggested that the improved haem synthesis was secondary to elimination in the urine of some iron compounds that block the active sulphydryl group of enzymes involved in the synthesis of haem. Whether this postulate is correct or not, these preliminary results should stimulate long-term follow-up studies of that aspect. Summary Desferrioxamine (an iron chelating agent) was given to 13 cases of thalassaemia in order to evaluate its efficiency in eliminating iron. The results show that 2 * 8 to 14-fold increases of urinary iron excretion followed a 1 g. daily dose of desferrioxamine. The chelating agent was more effective in longstanding severe cases with a greater iron load.
Desferrioxamine was observed to cause a reticulocytosis associated with increased haemopoietic response of the bone-marrow in 4 out of 6 patients studied. It is concluded that until more effective iron-eliminating agents are available, desferrioxamine should be administered to all cases of thalassaemia. Addendum After preparation of this manuscript, McDonald (1966) published a report on the effect of desferrioxamine in 4 cases of thalassaemia major. His excretion figures were slightly higher than ours for the 2 long-standing cases, and lower than ours for the 2 younger children. He did not report or comment on any reticulocyte response after desferrioxamine.
